Related to Record Revenues for Thermo Despite "Challenging Environment"

• Supreme Court’s Decision in Matrixx v. Siracusano Calls for More Disclosure of Adverse Events to Investors
  Side effects that are not statistically significant must also be divulged.
  
• NY Biotech Leaders Pursue Empire State of Mind with One-Stop Shop Proposal
  Think tank is also promoting tax credit extensions, tailored incentives, and easier tech transfer as cures for state’s life science blues.
  
• More VC But Fewer Deals Signal That Investors Are Becoming Even More Risk Averse
  While the love affair may be ending, venture capitalists are still opening up their wallets to later-stage companies.
  
• Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation
  Countries like China and Korea are growing to be more than just manufacturing hubs.
  
• M&A Activity Remains Important for Building Pipeline and Bottom Line
  Streamlining merged assets may be a challenge, but pros tip the balance in favor of mega takeovers.
  
• Growth Strategies for Tool Companies—Acquisition or R&D?
  Top players have grown largely through huge takeovers, but organic growth cannot be forgotten.
  
• For Some Emerging Companies, the Road to Growth Connects the U.S. and China
  While American firms are tapping China’s size and regulatory path, Chinese biotechs are going west for money and expertise.
  
• Biopharma Venture Funds Are Stepping Up Where VC Firms Are Stepping Out
  Such deals bring corporate giants some control in technology developers, who in turn gain the possibility of an exit through M&A.
  
• Continuing Freeze in Credit Warms Biopharma to Royalty Monetization Deals
  Industry and academia are both turning to this type of financing for cash now.
  
• 2011’s Five Biggest Biopharma Acquisitions Provide Clues for What’s Ahead
  Purchase of biotech giant Genzyme by Sanofi for $20.1 billion topped the list.
  
• This Year’s M&As Among Life Science Tool Firms Show Interest in Molecular Diagnostics
  Coming in at number one is Danaher’s purchase of diagnostic maker Beckman Coulter for $6.8 billion.
  
• M&A Activity Likely to Stay Hot in 2012 Though Blockbusters May Be Fewer
  Companies are looking down the road to padding their pipelines for long-term growth.
  
• Private Exchanges Emerge as an Alternative Financing Strategy
  Firms can stay private but trade their shares on these exchanges.
  
• Biopharma Will Need More than New Law to Embrace Crowdfunding
  Since product development takes longer and industry has more regulation, financing alternative has yet to prove itself.
  
• As Investors Eschew Risk, More M&A Deals Combine Cash with Milestone-Based Fees
  Buyers can hedge their bets, and sellers can ask for more contingent on pipeline assets.
  
• This Month Last Year: Shire and Thermo Fisher’s Acquisitions and Geron’s hESC Plans
  While Geron’s good news in May 2011 didn’t last long, Shire and Thermo hope their moves strengthen their businesses.
  
• Even If Bills to Hasten Drug Approvals Pass, Investments May Remain Dry Longer than Stakeholders Claim
  Accelerated approval of any form will likely not sufficiently irrigate the valley of death.
  
• Recent Flurry of New Life Science Funds Aim to Start Bridging the Valley of Death
  It remains to be seen whether these partnerships will succeed in advancing more medicines.
  
• Biopharma Job Outlook Bleak through Mid-Decade
  Restructuring, outsourcing, and patent expirations have combined to create a tumultuous job market.
  
• NIH Taps 25 Schools to Receive Top Dollars
  Did your alma mater make the list?